Non Alcoholic Fatty Liver Disease Stocks List

Symbol	Grade	Name	% Change
GALT	C	Galectin Therapeutics Inc.	-3.37
ALGS	B	Aligos Therapeutics, Inc.	8.74
AKRO	B	Akero Therapeutics, Inc.	1.84
BLTE	B	Belite Bio, Inc.	-0.10

Symbol	Grade	Name	Weight
OZEM	F	Roundhill GLP-1 & Weight Loss ETF	5.36
ADPV	A	Adaptiv Select ETF	2.72
THNR	F	Amplify Weight Loss Drug & Treatment ETF	2.72
BBC	D	Virtus LifeSci Biotech Clinical Trials ETF	2.4
XBI	D	SPDR S&P Biotech ETF	2.0

Compare ETFs

Compare ADPV to BBC Compare OZEM to THNR Compare THNR to BBC

Date	Stock	Title
Nov 20	BLTE	Belite Bio: Interesting Science, But Quite A Few Worries
Nov 19	ALGS	Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Nov 18	AKRO	Akero a new buy at Citi on liver disease asset
Nov 18	GALT	Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Nov 15	AKRO	Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024

Non Alcoholic Fatty Liver Disease: Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver, causing inflammation and damage. It is the most common form of liver disease in the United States, affecting up to 25% of the population. NAFLD is closely linked to obesity, diabetes, and high cholesterol, and can lead to serious complications such as cirrhosis and liver cancer. Treatment typically involves lifestyle changes such as weight loss, exercise, and a healthy diet.